SLS Shares Fall 3.2% in Two-Day Slide as Institutional Positions Diverge Before AML Trial Update
SLS•SLS shares slipped for a second straight session, including a 3.16% drop on Wednesday, as mixed institutional activity surfaced. Investors are positioning ahead of a scheduled AML trial update set for mid-July, reflecting divergent bets on potential compliance penalties.
1. Two-Day Losing Streak in SLS Stock
SLS shares declined for a second consecutive session, with Wednesday’s 3.16% drop extending the slide. Trading volume exceeded the ten-day average as bearish momentum picked up following a modest rebound earlier in the week.
2. Mixed Institutional Activity
Fund reports show divergent moves: several asset managers trimmed stakes by 5–10% in recent days, while a handful of hedge funds added to positions, betting on favorable trial outcomes. Short interest remains elevated at roughly 8% of the float, underscoring skepticism among some market participants.
3. Key AML Trial Update Approaching
A mid-July update in SLS’s high-profile AML compliance trial looms as a critical catalyst. Market participants are weighing potential fines or operational restrictions that could materialize from the court ruling, driving the current positioning shift.
